Stay updated with breaking news from Executive Albert Bourla. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation
Chief Executive Albert Bourla says 2021 was a 'watershed year' for drugmaker, with its efforts during the pandemic 'fundamentally changed our company forever'
NEW YORK - Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.
Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.
Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its inoculation.